Here's a regulatory headache that could affect your next trip to the pharmacy: a federal court has just pressed pause on the work of a key U.S. vaccine advisory panel. According to reports, this move throws the system for recommending COVID-19, flu, and other shots into disarray and raises big questions about whether insurance will cover newly approved vaccines.
U.S. District Judge Brian Murphy of the District of Massachusetts issued a ruling that halted the Advisory Committee on Immunization Practices (ACIP). The judge found that most of the members appointed under Health and Human Services Secretary Robert F. Kennedy Jr. were likely unqualified. The order effectively blocks the panel from issuing any new recommendations while the legal fight plays out. In the meantime, the old immunization guidance is back in effect.
A Panel Overhaul, Now in Legal Trouble
So how did we get here? Back in June 2025, Kennedy dismissed every sitting member of the ACIP. He replaced them with individuals reportedly skeptical of COVID-19 vaccine mandates, then added five more members in September without what the court deemed rigorous vetting. This overhaul was part of a broader shift, which included an announcement by President Trump on Truth Social about reducing the number of recommended vaccines from 72 to 11. Pfizer Inc. (PFE) CEO Albert Bourla called Kennedy's stance "anti-science."
Fall Vaccine Season Thrown Into Uncertainty
This court order hits at a particularly awkward time. In a normal year, the ACIP reviews and updates its recommendations for COVID and flu shots at its June meeting. Seasonal flu vaccines have a long-standing universal recommendation and might not need a fresh vote. But COVID vaccines are a different story—they're modified annually and have a shorter track record, which makes their recommendation status legally fuzzy without a functioning panel.
Complicating matters is insurance coverage. AHIP, the health insurance trade group, has said it will cover all vaccines recommended by the ACIP as of September 1, 2025, through the end of 2026. But what happens after that window, or for vaccines approved now? That's suddenly a very open question.
Approved Vaccines Stuck in Regulatory Purgatory
The freeze doesn't just affect theoretical discussions; it leaves several already FDA-approved vaccines in limbo, waiting for recommendations they may not get. Three RSV vaccines for adults aged 18 to 49 who are at elevated risk are in this boat: Pfizer Inc.'s (PFE) Abrysvo, Moderna Inc.'s (MRNA) mResvia, and GSK Plc's (GSK) Arexvy. Right now, they're only recommended for adults 75 and older and high-risk adults aged 50 to 74.
Merck & Co. Inc.'s (MRK) Enflonsia, a monoclonal antibody approved to prevent RSV in infants, also faces uncertainty, though Merck has said the product wasn't a focus of the litigation. And a long-running ACIP review about whether fewer doses of the HPV vaccine could still prevent cervical cancer has also been paused.
Pipeline Products Face the Same Gap
The paralysis extends to vaccines still in the pipeline. Moderna's (MRNA) experimental mRNA-based flu vaccine, which would be a first of its kind in the U.S., is awaiting an FDA decision expected by early August. If approved, it could hit the market without a federal recommendation because there's no functioning ACIP to give one.
Pfizer (PFE) and Valneva SE's Lyme disease vaccine, which showed roughly 70% efficacy in a late-stage trial, faces the same problem if it wins FDA approval.
Kennedy hasn't yet said whether he'll try to reconfigure the panel, appeal the ruling, or do both. His appearance before the House Ways and Means Committee earlier this month, where he defended a proposed 12.5% cut to the HHS budget, already drew sharp criticism from Congress over vaccine policy changes and declining vaccination rates. Now, with a court order on the books, the path forward for the nation's vaccine recommendations is officially stuck in neutral.
.jpeg)
